MIRA Pharmaceuticals, Inc.
MIRA
$1.04
$0.04584.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.71M | 5.81M | 6.94M | 6.89M | 6.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.02M | 8.64M | 9.72M | 8.95M | 8.53M |
| Operating Income | -8.02M | -8.64M | -9.72M | -8.95M | -8.53M |
| Income Before Tax | -7.85M | -11.24M | -12.78M | -12.36M | -11.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.85 | -11.24 | -12.78 | -12.36 | -11.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.85M | -11.24M | -12.78M | -12.36M | -11.98M |
| EBIT | -8.02M | -8.64M | -9.72M | -8.95M | -8.53M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.48 | -0.73 | -0.86 | -0.84 | -0.83 |
| Normalized Basic EPS | -0.30 | -0.46 | -0.54 | -0.52 | -0.52 |
| EPS Diluted | -0.48 | -0.73 | -0.86 | -0.84 | -0.83 |
| Normalized Diluted EPS | -0.30 | -0.46 | -0.54 | -0.52 | -0.52 |
| Average Basic Shares Outstanding | 66.12M | 64.34M | 62.91M | 61.44M | 59.48M |
| Average Diluted Shares Outstanding | 66.12M | 64.34M | 62.91M | 61.44M | 59.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |